Aquestive(US:AQST) Globenewswire·2026-03-16 20:00Core Viewpoint - The company, Aquestive Therapeutics, Inc. (NASDAQ: AQST), faced significant discrepancies between its optimistic projections regarding the Anaphylm regulatory approval and the actual outcomes, leading to a substantial decline in stock value and potential legal repercussions for misleading investors [2][6][8]. Group 1: Company Projections - Throughout the Class Period (June 16, 2025, to January 8, 2026), the company expressed strong confidence in the Anaphylm regulatory path, stating it was "one step closer" to approval after FDA acceptance of the NDA [3] - On August 12, 2025, the company assured investors it was "on track" across all regulatory elements, including FDA review and pre-commercial launch activities [4] - On November 5, 2025, the company reiterated that its NDA was "on track" for the scheduled January 31, 2026 PDUFA goal date, citing "strong execution" [4] Group 2: Actual Outcomes - On January 9, 2026, the FDA identified deficiencies in the NDA that precluded discussions of labeling and post-marketing commitments, indicating that the PDUFA date could not be met [5] - By January 30, 2026, the FDA issued a Complete Response Letter citing multiple failures in human factors validation studies, including usability concerns [5] - The promised FDA approval by January 31, 2026, was replaced with a delay to at least Q1 2027, and the company now faces a resubmission estimated for Q3 2026 [6] Group 3: Legal Implications - The securities action alleges that management was aware of the deficiencies in the Anaphylm NDA while providing misleadingly confident statements to investors, which artificially inflated AQST's stock price [8] - The gap between the company's assurances and the FDA's communications raises serious questions about the accuracy of the information provided to shareholders during the Class Period [6]